Krystal Biotech (NASDAQ:KRYS – Get Rating) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Thursday, Zacks.com reports. The brokerage currently has a $71.00 price objective on the stock. Zacks Investment Research‘s price target indicates a potential upside of 6.67% […]
Krystal Biotech (NASDAQ:KRYS – Get Rating) and Cardiff Oncology (NASDAQ:CRDF – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, risk, earnings, dividends, valuation, analyst recommendations and institutional ownership. Volatility & Risk Krystal Biotech has a beta of […]
Shares of Krystal Biotech, Inc. (NASDAQ:KRYS – Get Rating) have received a consensus recommendation of “Buy” from the eight research firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The average twelve-month price target […]
Krystal Biotech (NASDAQ:KRYS – Get Rating) posted its earnings results on Sunday. The company reported ($0.95) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.72) by ($0.23), Yahoo Finance reports. KRYS opened at $64.15 on Wednesday. Krystal Biotech has a 52-week low of $38.86 and a 52-week high of $102.99. The […]